Please login to the form below

Not currently logged in
Email:
Password:

metformin

This page shows the latest metformin news and features for those working in and with pharma, biotech and healthcare.

Merck to pilot digital behavioural change programme

Merck to pilot digital behavioural change programme

Merck last year received UK approval for its mature oral diabetes drug Glucophage (metformin) to treat non-diabetic hyperglycaemia or pre-diabetes and is looking to add ‘beyond the pill’services

Latest news

More from news
Approximately 6 fully matching, plus 180 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Complements are products that are often used together. Sometimes this distinction becomes blurred, as with metformin, which is a treatment for type II diabetes in its own right and also used ... market. The large product beside Januvia is metformin that,

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage. ... We probably have the broadest offering of products in diabetes in that middle space from when people start in

  • Pharma deals during November 2013 Pharma deals during November 2013

    The all-cash transaction is expected to close in Q1 2014. The combined company will market 22 products, including Xifaxan (rifaximin; 2012 sales of $514.5m) and Santarus' therapy Glumetza (metformin)

  • Rise of generic medicines in Portugal Rise of generic medicines in Portugal

    Generics bestsellers in volume. Simvastatin. Alprazolam. Oneprazol. Ibuprofen. Paracetamol. Metformin. Nimesulide.

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    The most commonly used oral/ non-insulin injectables are Metformin (37 per cent), Glucobay (21 per cent), Glipizide (15 per cent) and Tangshiping (11 per cent). ... In March 2013, Merck Serono and Bristol-Myers Squibb struck a deal to co-promote a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics